Kartik Sivaraaman, MD
Neurology · Richmond, VANPI 1962651026
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $4,544 and has fallen 75.2% since, to $1,126 in 2025.
Across 276 payments — averaging $41.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Bristol Myers Squibb$2K
- AbbVie$886
- Argenx US, Inc.$515
- Supernus Pharmaceuticals, Inc.$352
- plus $3K from 52 others
What the payments were for
- Consulting fees$4,40038%
- Speaking & faculty fees$390%
- Travel & lodging$1,11510%
- Food & beverage$5,94552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cenobamate$2,450
- ZEPOSIA$218
How this compares
$11,500 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 77 | $2,624 |
| Levetiracetam ErLevetiracetam | 22 | $947 |
| Gabapentin | 53 | $622 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $156 |
| Donepezil Hcl | 12 | $150 |
Paid to pharmacies, not to this prescriber.
Other neurology in Richmond
- Catherine HamRichmond$603K
- Daniel HardyRichmond$382K
- Myla GoldmanRichmond$132K
- Alan SchulmanRichmond$104K
- Warren FeltonRichmond$96K
- John WittmanRichmond$61K
- Matthew BoyceRichmond$56K
- Leslie CloudRichmond$46K
- Jonathan BekensteinRichmond$37K
- Jessica LehositRichmond$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.